Reuters logo
BRIEF-Daily blood glucose measures in phase 3 clinical trials showed better stability with Sanofi's toujeo vs insulin glargine 100 units/ml
September 13, 2017 / 11:16 AM / 8 days ago

BRIEF-Daily blood glucose measures in phase 3 clinical trials showed better stability with Sanofi's toujeo vs insulin glargine 100 units/ml

Sept 13 (Reuters) - Sanofi SA

* Daily blood glucose measures in phase 3 clinical trials demonstrated better stability with Sanofi’s toujeo versus insulin glargine 100 units/ml

* Sanofi - ‍improvements in blood glucose stability were statistically significant in edition 2 and senior, and for night-time measurements in edition 3​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below